Tradestie Institutional Equity Comparison Engine
SRZN vs COCP โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (3โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus COCP at N/M Forward P/E and -3063.6% operating margin (+26.9% YoY). In options structure, SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
SRZN N/M vs COCP N/M Fwd P/E
Growth & Margin Winner
SRZN
Op Margin -485.4% vs -3063.6% ยท YoY +408.6% vs +26.9%
Momentum & Technical Winner
SRZN
1Y +131.0% vs -1.9% ยท 52W Pos 69% vs 20%
Options & Structure Winner
SRZN
CONSOLIDATION (5th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.98
-7.24% 1D
Market Cap
$602.5M
1M Return
+25.76%
1Y Return
+130.97%
Forward P/E
N/M
Unified AI Score
33.2 / 100
SELL
Tech 50.0
Fund 34.0
Flow 65.0
Mom 40.0
COCP
NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.01
+3.3% 1D
Market Cap
$18.9M
1M Return
+6.7%
1Y Return
-1.94%
Forward P/E
N/M
Unified AI Score
38.7 / 100
SELL
Tech 25.0
Fund 43.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
SRZN +130.97%
COCP -1.94%
Spread: +132.91 pp (SRZN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SRZN Revenue | COCP Revenue | SRZN Op. Margin | COCP Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2011 | N/A | $10M | N/A | -30.6% | COCP |
| FY2019 | N/A | $10M | N/A | -737.4% | COCP |
| FY2020 | N/A | $0M | N/A | -476.0% | COCP |
| FY2022 | $10M | N/A | -354.7% | N/A | SRZN |
| FY2024 | $10M | N/A | -239.7% | N/A | SRZN |
| FY2025 | $0M | N/A | -1210.6% | N/A | SRZN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | SRZN | COCP | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $602.5M | $18.9M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +408.6% | +26.9% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | -485.4% | -3063.6% | Higher Margin | SRZN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -62.8% | -311.7% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 69% ($12โ$38) | 20% ($1โ$2) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 1.29ฮฒ ยท 67% Vol | 0.98ฮฒ ยท 54% Vol | Lower Realized Risk | COCP |
| Unified Institutional Score Composite Signal | 33.2 / 100 (SELL) | 38.7 / 100 (SELL) | Higher Composite | COCP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full SRZN vs COCP Buy Guide
SRZN
CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
COCP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither SRZN nor COCP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.